Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02970318




Registration number
NCT02970318
Ethics application status
Date submitted
18/11/2016
Date registered
22/11/2016
Date last updated
29/08/2024

Titles & IDs
Public title
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Scientific title
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
Secondary ID [1] 0 0
2015-004454-17
Secondary ID [2] 0 0
ACE-CL-309
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Acalabrutinib (ACP-196)
Treatment: Drugs - Rituximab
Treatment: Drugs - Idelalisib
Treatment: Drugs - Bendamustine

Experimental: Acalabrutinib (ACP-196) - Acalabrutinib (ACP-196) Monotherapy

Active comparator: Rituximab Plus Idelalisib or Bendamustine - Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine


Treatment: Drugs: Acalabrutinib (ACP-196)
Acalabrutinib monotherapy

Treatment: Drugs: Rituximab
Rituximab in combination with idelalisib or bendamustine

Treatment: Drugs: Idelalisib
Idelalisib in combination with rituximab

Treatment: Drugs: Bendamustine
Bendamustine in combination with rituximab
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment
Timepoint [1] 0 0
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Secondary outcome [1] 0 0
Progression-free Survival (PFS) Per Investigator Assessment
Timepoint [1] 0 0
From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up.
Secondary outcome [2] 0 0
IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis
Timepoint [2] 0 0
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Secondary outcome [3] 0 0
Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021
Timepoint [3] 0 0
Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up.
Secondary outcome [4] 0 0
Overall Survival (OS)
Timepoint [4] 0 0
From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up.
Secondary outcome [5] 0 0
Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.
Timepoint [5] 0 0
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Secondary outcome [6] 0 0
Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff
Timepoint [6] 0 0
Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up.
Secondary outcome [7] 0 0
Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff
Timepoint [7] 0 0
From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause or study discontinuation or data cutoff date on 03Sep2021,, whichever came first up to 53 months of follow-up.

Eligibility
Key inclusion criteria
1. Men and women = 18 years of age.
2. ECOG performance status of 0 to 2.
3. Diagnosis of CLL that meets published diagnostic criteria (Hallek 2008):

1. Monoclonal B-cells (either kappa or lambda light chain restricted) that are clonally co-expressing = 1 B-cell marker (CD19, CD20, or CD23) and CD5.
2. Prolymphocytes may comprise = 55% of blood lymphocytes.
3. Presence of = 5 x 10^9 B lymphocytes/L (5000/µL) in the peripheral blood (at any point since initial diagnosis).
4. Must have documented CD20-positive CLL.
5. Active disease meeting = 1 of the following IWCLL 2008 criteria for requiring treatment:

1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets < 100,000/µL).
2. Massive (i.e., = 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
3. Massive nodes (i.e., = 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
4. Progressive lymphocytosis with an increase of > 50% over a 2-month period or a LDT of < 6 months. LDT may be obtained by linear regression extrapolation of ALC obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of < 30 x 10^9/L (30,000/µL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
5. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy.
6. Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as = 1 of the following disease-related symptoms or signs:

i. Unintentional weight loss = 10% within the previous 6 months before screening.

ii. Significant fatigue (ECOG performance score 2; inability to work or perform usual activities).

iii. Fevers higher than 100.5°F or 38.0°C for = 2 weeks before screening without evidence of infection.

iv. Night sweats for > 1 month before screening without evidence of infection.
6. Meet the following laboratory parameters:

1. ANC = 750 cells/µL (0.75 x 10^9/L), or = 500 cells/µL (0.50 x 10^9/L) in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
2. Platelet count = 50,000 cells/µL (50 x 10^9/L), or = 30,000 cells/µL (30 x 10^9/L) in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded. If an Investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be = 75,000 cells/µL (75 x 10^9/L).
3. Serum AST and ALT = 2.0 x ULN.
4. Total bilirubin = 1.5 x ULN.
5. Estimated creatinine clearance of = 30 mL/min, calculated using the formula of Cockcroft and Gault [(140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female].
7. Must have received = 1 prior systemic therapies for CLL. Note: Single-agent steroids or localized radiation are not considered a prior line of therapy. If a single-agent anti-CD20 antibody was previously administered, subjects must have received = 2 doses.
8. Women who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib, 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5.
9. Men who are sexually active and can beget children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5.
10. Men must agree to refrain from sperm donation during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
11. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules without difficulty.
12. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known CNS lymphoma or leukemia.
2. Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
3. Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary to autoimmune destruction within the screening period or requirement for high doses of steroids (> 20 mg daily of prednisone or equivalent).
4. Prior exposure to a BCL-2 inhibitor (e.g., venetoclax/ABT-199) or a BCR inhibitor (e.g., BTK inhibitors or PI3K inhibitors). Prior bendamustine is allowed if Investigator's choice for treatment in Arm B is idelalisib with rituximab. Bendamustine retreatment is allowed if the prior response to bendamustine lasted > 24 months.
5. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug.
6. Corticosteroid use > 20 mg daily prednisone equivalent within 1 week before first dose of study drug, except as indicated for other medical conditions such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of study drug or contrast. For example, subjects requiring steroids at daily doses > 20 mg prednisone equivalent systemic exposure daily, or those who are administered steroids for leukemia control or white blood cell count lowering are excluded.
7. Prior radio- or toxin-conjugated antibody therapy.
8. Prior allogeneic stem cell transplant or prior autologous transplant within 6 months of first dose of study drug(s) or presence of graft-vs-host disease or receiving treatment for graft-vs-host disease.
9. Major surgical procedure within 30 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.
10. History of prior malignancy except for the following:

1. Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician.
2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer.
3. Adequately treated carcinoma in situ without current evidence of disease.
11. Significant cardiovascular disease such as uncontrolled or untreated symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or QTc > 480 msec (calculated using Fridericia's formula: QT/RR^0.33) at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
12. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
13. Received a live virus vaccination within 28 days of first dose of study drug.
14. Known history of infection with HIV or any uncontrolled active systemic infection (e.g., bacterial, viral, or fungal). For study sites in Germany: active infection with human immunodeficiency virus (seropositivity for HIV-1 or HIV-2 antibodies, and if positive, reactivity against the HIV-specific p24 antigen).
15. Active CMV infection (active viremia as evidenced by positive polymerase chain reaction [PCR] result for CMV DNA).
16. Serologic status reflecting active hepatitis B or C infection.

1. Subjects who are anti-HBc positive and who are surface antigen negative will need to have a negative PCR result before randomization. Those who are HbsAg-positive or hepatitis B PCR positive will be excluded.
2. Subjects who are hepatitis C antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded.
17. Ongoing, drug-induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
18. History of or ongoing drug-induced pneumonitis.
19. History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis.
20. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
21. History of bleeding diathesis (e.g., hemophilia, von Willebrand disease).
22. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug.
23. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
24. Requires treatment with a strong CYP3A inhibitor/inducer.
25. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.
26. Breast feeding or pregnant.
27. Concurrent participation in another therapeutic clinical trial.
28. Prothrombin time/INR or aPTT (in the absence of a Lupus anticoagulant) > 2.0 x ULN. Exception: Subjects receiving warfarin are excluded, however, those receiving other anticoagulant therapy who have a higher INR/aPTT may be permitted to enroll to this study after discussion with the medical monitor.
29. History of confirmed progressive multifocal leukoencephalopathy (PML)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/02/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2027
Actual
Sample size
Target
Accrual to date
Final
310
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Adelaide
Recruitment hospital [2] 0 0
Research Site - Box Hill
Recruitment hospital [3] 0 0
Research Site - Frankston
Recruitment hospital [4] 0 0
Research Site - Geelong
Recruitment hospital [5] 0 0
Research Site - Gosford
Recruitment hospital [6] 0 0
Research Site - Hobart
Recruitment hospital [7] 0 0
Research Site - Kogarah
Recruitment hospital [8] 0 0
Research Site - Murdoch
Recruitment hospital [9] 0 0
Research Site - Nedlands
Recruitment hospital [10] 0 0
Research Site - South Brisbane
Recruitment hospital [11] 0 0
Research Site - Woodville
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
3199 - Frankston
Recruitment postcode(s) [4] 0 0
3220 - Geelong
Recruitment postcode(s) [5] 0 0
2250 - Gosford
Recruitment postcode(s) [6] 0 0
7000 - Hobart
Recruitment postcode(s) [7] 0 0
2217 - Kogarah
Recruitment postcode(s) [8] 0 0
6150 - Murdoch
Recruitment postcode(s) [9] 0 0
6009 - Nedlands
Recruitment postcode(s) [10] 0 0
4101 - South Brisbane
Recruitment postcode(s) [11] 0 0
5011 - Woodville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Nebraska
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
Austria
State/province [13] 0 0
Linz
Country [14] 0 0
Austria
State/province [14] 0 0
Salzburg
Country [15] 0 0
Austria
State/province [15] 0 0
Wels
Country [16] 0 0
Austria
State/province [16] 0 0
Wien
Country [17] 0 0
Belgium
State/province [17] 0 0
Antwerpen
Country [18] 0 0
Belgium
State/province [18] 0 0
Ghent
Country [19] 0 0
Belgium
State/province [19] 0 0
Roeselare
Country [20] 0 0
Belgium
State/province [20] 0 0
Yvoir
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Pleven
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Plovdiv
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Stara Zagora
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Vratsa
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Canada
State/province [26] 0 0
Calgary
Country [27] 0 0
Canada
State/province [27] 0 0
Montreal
Country [28] 0 0
Canada
State/province [28] 0 0
Ottawa
Country [29] 0 0
Canada
State/province [29] 0 0
Regina
Country [30] 0 0
Canada
State/province [30] 0 0
Saint John
Country [31] 0 0
Canada
State/province [31] 0 0
Toronto
Country [32] 0 0
Croatia
State/province [32] 0 0
Zadar
Country [33] 0 0
Croatia
State/province [33] 0 0
Zagreb
Country [34] 0 0
Czechia
State/province [34] 0 0
Brno
Country [35] 0 0
Czechia
State/province [35] 0 0
Novy Hradec Kralove
Country [36] 0 0
Czechia
State/province [36] 0 0
Olomouc
Country [37] 0 0
Czechia
State/province [37] 0 0
Ostrava Poruba
Country [38] 0 0
Czechia
State/province [38] 0 0
Plzen - Lochotin
Country [39] 0 0
Czechia
State/province [39] 0 0
Praha 10
Country [40] 0 0
France
State/province [40] 0 0
Bordeaux
Country [41] 0 0
France
State/province [41] 0 0
Brest
Country [42] 0 0
France
State/province [42] 0 0
Montpellier
Country [43] 0 0
France
State/province [43] 0 0
Nantes cedex 1
Country [44] 0 0
France
State/province [44] 0 0
Paris cedex 13
Country [45] 0 0
France
State/province [45] 0 0
Paris
Country [46] 0 0
France
State/province [46] 0 0
Perpignan
Country [47] 0 0
France
State/province [47] 0 0
Provence Alpes Cote D'Azur
Country [48] 0 0
France
State/province [48] 0 0
Rennes Cedex
Country [49] 0 0
France
State/province [49] 0 0
Rouen
Country [50] 0 0
Germany
State/province [50] 0 0
Aschaffenburg
Country [51] 0 0
Germany
State/province [51] 0 0
Dresden
Country [52] 0 0
Germany
State/province [52] 0 0
Munchen
Country [53] 0 0
Germany
State/province [53] 0 0
Mutlangen
Country [54] 0 0
Germany
State/province [54] 0 0
Ulm
Country [55] 0 0
Hong Kong
State/province [55] 0 0
HongKong
Country [56] 0 0
Hong Kong
State/province [56] 0 0
Pok Fu Lam
Country [57] 0 0
Hungary
State/province [57] 0 0
Budapest
Country [58] 0 0
Hungary
State/province [58] 0 0
Debrecen
Country [59] 0 0
Hungary
State/province [59] 0 0
Gyula
Country [60] 0 0
Hungary
State/province [60] 0 0
Kaposvár
Country [61] 0 0
Israel
State/province [61] 0 0
Ashkelon
Country [62] 0 0
Israel
State/province [62] 0 0
Haifa
Country [63] 0 0
Israel
State/province [63] 0 0
Jerusalem
Country [64] 0 0
Israel
State/province [64] 0 0
Kfar Saba
Country [65] 0 0
Israel
State/province [65] 0 0
Nahariya
Country [66] 0 0
Israel
State/province [66] 0 0
Petah Tikvah
Country [67] 0 0
Italy
State/province [67] 0 0
Aviano
Country [68] 0 0
Italy
State/province [68] 0 0
Bergamo
Country [69] 0 0
Italy
State/province [69] 0 0
Brescia
Country [70] 0 0
Italy
State/province [70] 0 0
Firenze
Country [71] 0 0
Italy
State/province [71] 0 0
Genova
Country [72] 0 0
Italy
State/province [72] 0 0
Meldola
Country [73] 0 0
Italy
State/province [73] 0 0
Milano
Country [74] 0 0
Italy
State/province [74] 0 0
Milan
Country [75] 0 0
Italy
State/province [75] 0 0
Modena
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Busan
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Daegu
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Dong-gu
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Gyeonggi-do
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Incheon
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Jeonju-si
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Seoul
Country [83] 0 0
New Zealand
State/province [83] 0 0
Addington
Country [84] 0 0
New Zealand
State/province [84] 0 0
Dunedin
Country [85] 0 0
New Zealand
State/province [85] 0 0
Palmerston North
Country [86] 0 0
New Zealand
State/province [86] 0 0
Tauranga
Country [87] 0 0
Poland
State/province [87] 0 0
Bialystok
Country [88] 0 0
Poland
State/province [88] 0 0
Bydgoszcz
Country [89] 0 0
Poland
State/province [89] 0 0
Gdansk
Country [90] 0 0
Poland
State/province [90] 0 0
Kraków
Country [91] 0 0
Poland
State/province [91] 0 0
Lodz
Country [92] 0 0
Poland
State/province [92] 0 0
Lublin
Country [93] 0 0
Poland
State/province [93] 0 0
Woj. Podkarpackie
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Novosibirsk
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Obninsk
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Penza
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Ryazan
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Sochi
Country [99] 0 0
Russian Federation
State/province [99] 0 0
St. Petersburg
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Tula
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Volgograd
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Yaroslavl
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Yekaterinburg
Country [104] 0 0
Singapore
State/province [104] 0 0
SGP
Country [105] 0 0
Slovakia
State/province [105] 0 0
Bratislava
Country [106] 0 0
Slovakia
State/province [106] 0 0
Kosice
Country [107] 0 0
Spain
State/province [107] 0 0
Badalona
Country [108] 0 0
Spain
State/province [108] 0 0
Madrid
Country [109] 0 0
Spain
State/province [109] 0 0
Majadahonda
Country [110] 0 0
Spain
State/province [110] 0 0
Salamanca
Country [111] 0 0
Spain
State/province [111] 0 0
Santander
Country [112] 0 0
Spain
State/province [112] 0 0
Valencia
Country [113] 0 0
Sweden
State/province [113] 0 0
Goeteborg
Country [114] 0 0
Sweden
State/province [114] 0 0
Lulea
Country [115] 0 0
Sweden
State/province [115] 0 0
Stockholm
Country [116] 0 0
Taiwan
State/province [116] 0 0
Hualien
Country [117] 0 0
Taiwan
State/province [117] 0 0
Tainan
Country [118] 0 0
Taiwan
State/province [118] 0 0
Taipei
Country [119] 0 0
Ukraine
State/province [119] 0 0
Cherkasy
Country [120] 0 0
Ukraine
State/province [120] 0 0
Dnipropetrovsk
Country [121] 0 0
Ukraine
State/province [121] 0 0
Ivano-Frankivsk
Country [122] 0 0
Ukraine
State/province [122] 0 0
Khmelnytsky
Country [123] 0 0
Ukraine
State/province [123] 0 0
Kyiv
Country [124] 0 0
Ukraine
State/province [124] 0 0
Zhytomir
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Birmingham
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Cambridge
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Canterbury
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Leicester
Country [129] 0 0
United Kingdom
State/province [129] 0 0
London
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Maidstone
Country [131] 0 0
United Kingdom
State/province [131] 0 0
Manchester
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Southampton
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Acerta Pharma BV
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
Trial website
https://clinicaltrials.gov/study/NCT02970318
Trial related presentations / publications
Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D. Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia. J Patient Rep Outcomes. 2021 Mar 11;5(1):27. doi: 10.1186/s41687-021-00294-1.
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27.
Public notes

Contacts
Principal investigator
Name 0 0
Acerta Clinical Trials
Address 0 0
1-888-292-9613; [email protected]
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02970318